Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2720-2725

  Bowers, Dana R ^a,c   Cao, Henry ^a   Zhou, Jian ^a   Ledesma, Kimberly R ^a   Sun, Dongxu ^b   Lomovskaya, Olga ^b   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b Rempex Pharmaceuticals   (United States)

^c Kingman Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINOCYCLINE; POLYMYXIN B; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; ELIMINATION HALF-LIFE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG BURDEN; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NEUTROPENIA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION; ANIMAL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; MICE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PNEUMONIA; POLYMYXIN B;

EID: 84931274837     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04110-14     Document Type: Article

References (31)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
2. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. 2007. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 45:3352-3359. http://dx.doi.org/10.1128/JCM.01284-07.
3. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA. 2012. Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. Diagn Microbiol Infect Dis 73:267-270. http://dx.doi.org/10.1016/j.diagmicrobio.2012.04.002.
4. Neonakis IK, Spandidos DA, Petinaki E. 2011. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents 37: 102-109. http://dx.doi.org/10.1016/j.ijantimicag.2010.10.014.
5. Garcia-Quintanilla M, Pulido MR, Lopez-Rojas R, Pachon J, Mc-Connell MJ. 2013. Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol 21:157-163. http://dx.doi.org/10.1016/j.tim.2012.12.002.
6. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A. 2007. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13:97-103. http://dx.doi.org/10.3201/eid1301.060716.
7. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. 2007. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 26:793-800. http://dx.doi.org/10.1007/s10096-007-0371-8.
8. Karageorgopoulos DE, Falagas ME. 2008. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8:751-762. http://dx.doi.org/10.1016/S1473-3099(08)70279-2.
9. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48:753-757. http://dx.doi.org/10.1128/AAC.48.3.753-757.2004.
10. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, Millar M. 2008. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 27:607-612. http://dx.doi.org/10.1007/s10096-008-0473-y.
11. Galani I, Orlandou K, Moraitou H, Petrikkos G, Souli M. 2014. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 43:370-374. http://dx.doi.org/10.1016/j.ijantimicag.2013.12.010.
12. Fischbach MA, Walsh CT. 2009. Antibiotics for emerging pathogens. Science 325:1089-1093. http://dx.doi.org/10.1126/science.1176667.
13. Sitaram N, Nagaraj R. 1999. Interaction of antimicrobial peptides with biological and model membranes: structural and charge requirements for activity. Biochim Biophys Acta 1462:29-54. http://dx.doi.org/10.1016/S0005-2736(99)00199-6.
14. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. 2006. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 44:2974-2976. http://dx.doi.org/10.1128/JCM.01021-06.
15. Cortez-Cordova J, Kumar A. 2011. Activity of the efflux pump inhibitor phenylalanine-arginine beta-naphthylamide against the AdeFGH pump of Acinetobacter baumannii. Int J Antimicrob Agents 37:420-424. http://dx.doi.org/10.1016/j.ijantimicag.2011.01.006.
16. Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. 2010. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J Infect Dis 201:889-897. http://dx.doi.org/10.1086/651024.
17. Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis RE. 2009. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagn Microbiol Infect Dis 64:427-433. http://dx.doi.org/10.1016/j.diagmicrobio.2009.03.031.
18. D'Argenio DZ, Schumitzky A. 1988. ADAPT II user's guide. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
19. He J, Gao S, Hu M, Chow DS, Tam VH. 2013. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 68:1104-1110. http://dx.doi.org/10.1093/jac/dks536.
20. Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH. 2013. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 207:786-793. http://dx.doi.org/10.1093/infdis/jis766.
21. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256-265. http://dx.doi.org/10.1093/jac/dkl224.
22. Kwa AL, Lim TP, Low JG, Hou J, Kurup A, Prince RA, Tam VH. 2008. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 60:163-167. http://dx.doi.org/10.1016/j.diagmicrobio.2007.08.008.
23. Falagas ME, Kopterides P, Siempos II. 2006. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 43:389. (Author reply, 43:389-390.) http://dx.doi.org/10.1086/505599.
24. Rodriguez-Bano J, Pascual A, Galvez J, Muniain MA, Rios MJ, Martinez-Martinez L, Perez-Cano R, Perea EJ. 2003. Acinetobacter baumannii bacteremia: clinical and prognostic features. Enferm Infecc Microbiol Clin 21:242-247. http://dx.doi.org/10.1016/S0213-005X(03)72930-9.
25. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. 2014. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305-2309. http://dx.doi.org/10.1093/jac/dku168.
26. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, Hsueh PR. 2007. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 13:196-198. http://dx.doi.org/10.1111/j.1469-0691.2006.01601.x.
27. Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA. 2007. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:1621-1626. http://dx.doi.org/10.1128/AAC.01099-06.
28. Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL. 2011. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6:e18485. http://dx.doi.org/10.1371/journal.pone.0018485.
29. Zhang Y, Chen F, Sun E, Ma R, Qu C, Ma L. 2013. In vitro antibacterial activity of combinations of fosfomycin, minocycline and polymyxin B on pan-drug-resistant Acinetobacter baumannii. Exp Ther Med 5:1737-1739. http://dx.doi.org/10.3892/etm.2013.1039.
30. He J, Abdelraouf K, Ledesma KR, Chow DS, Tam VH. 2013. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int J Antimicrob Agents 42:559-564. http://dx.doi.org/10.1016/j.ijantimicag.2013.07.009.
31. Elias LS, Konzen D, Krebs JM, Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65:2231-2237. http://dx.doi.org/10.1093/jac/dkq285.